美容护理/化妆品 福瑞达（600223.SH） 2025 年 08 月 24 日 投资评级：买入（维持） | 日期 | 2025/8/22 | | --- | --- | | 当前股价(元) | 8.52 | | 一年最高最低(元) | 9.42/5.74 | | 总市值(亿元) | 86.61 | | 流通市值(亿元) | 86.61 | | 总股本(亿股) | 10.17 | | 流通股本(亿股) | 10.17 | | 近 3 个月换手率(%) | 142.06 | 股价走势图 数据来源：聚源 -16% 0% 16% 32% 48% 64% 2024-08 2024-12 2025-04 福瑞达 沪深300 相关研究报告 《剔除地产业绩表现稳健，期待化妆 品业务稳中有升—公司信息更新报 告》-2025.3.26 《2024Q3 归母净利润同比-7.8%，化 妆品业务表现稳健—公司信息更新报 告》-2024.10.29 《剔除地产业务影响，2024H1 公司经 营情况稳健—公司信息更新报告》 -2024.8.24 2025 H1 业绩承压，期待化妆品业务调整修复 ——公司信息更新报告 公司发布半年报：20 ...

事件：公司发布2025 年中报。公司1H25 收入17.89 亿元（同比-7.1%，下同），归母净利润1.08 亿元 （-15.2%），扣非归母净利润1.05 亿元（-6.3%）；其中2Q25 收入9.13 亿元（-11.7%），归母净利润 0.57 亿元（-16.1%）。 风险提示：竞争加剧风险；化妆品销售不及预期风险；渠道拓展不及预期风险。 投资建议：公司坚持构建美与大健康生态体系，上半年颐莲品牌增势较好，原料业务贡献增长基本盘， 品牌建设稳步推进，期待瑷尔博士品牌调整完毕带动业绩修复。预计2025-2027 年归母净利润分别为 2.60/2.97/3.39 亿元，对应PE为33.3/29.1/25.6，维持"增持"评级。 化妆品业务颐莲实现高增，原料业务表现稳健。分业务看，1H25 化妆品实现收入10.94 亿元 （-7.7%），毛利率为62.0%（+0.6pct)，其中颐莲、瑷尔博士收入分别为5.54 亿元（+23.8%）/4.51 亿元 （-30.0%）；医药产品1H25实现收入2.07 亿元（-13.9%），毛利率51.8%（-0.3pct)；原料及衍生产品、 添加剂业务实现收入1.79 亿元（+ ...

Core Insights - The company reported a revenue of 1.79 billion yuan in the first half of 2025, with a net profit of 108 million yuan, and total assets of 6.037 billion yuan as of June 30, 2025 [1][2] Group 1: Cosmetics Business - The cosmetics segment generated a revenue of 1.094 billion yuan in the first half of 2025, with the Yilian brand achieving 554 million yuan, reflecting a year-on-year growth of 23.78% [2] - The Yilian brand launched a global spokesperson, Zhang Linghe, and held a summer spray festival, with spray product line sales reaching 482 million yuan, an increase of 43% [2] - The Aier Doctor brand reported a revenue of 451 million yuan, with new products like the 287 mask and 287 lotion, generating nearly 10 million yuan in sales within two months of launch [2] Group 2: Pharmaceutical Business - The pharmaceutical segment achieved a revenue of 207 million yuan, expanding its client base by over 200 hospitals and OTC customers [2] - Key products include children's flu medication and a popular pain relief product recognized at the Wuzhen Health Conference [2] - The company is actively developing food-medicine integration standards and collaborating with major clients to enhance raw material supply [2] Group 3: Raw Materials and Additives - The raw materials and additives segment reported a revenue of 179 million yuan, with hyaluronic acid sales reaching 116 million yuan, a year-on-year increase of 23.4% [3] - Medical-grade hyaluronic acid sales surged by 287.3%, totaling 16.08 million yuan [3] - The overall gross margin for the hyaluronic acid business improved to 47.1%, up by 8.5 percentage points [3] Group 4: Innovation and R&D - The company launched over 80 new products in the cosmetics sector, including the Aier Doctor 287 mask and Yilian purple essence water [3] - The company introduced a pioneering transdermal collagen technology, enhancing skin penetration by 27.5 times [3] - The company has made significant progress in medical device registrations and drug development, including obtaining production licenses for various products [3]

Core Viewpoint - The third China International Supply Chain Promotion Expo showcases the innovative practices of Shandong Lushang Group, emphasizing a new supply chain model that integrates product co-research, channel collaboration, ecological construction, and financial empowerment [1][3]. Group 1: Supply Chain Innovations - Lushang Group utilizes a "one plate of goods" approach to overcome traditional resource fragmentation and channel disconnection, forming a supply chain platform that integrates various internal and external resources [3]. - The company will present its supply chain highlights at the expo, including products from its subsidiary, Furuida, which features advanced technologies and sustainable practices in the beauty industry [3][4]. - Furuida's star products, such as the hyaluronic acid series and patented collagen technology, will be showcased, demonstrating significant advancements in product efficacy and sustainability [3][4]. Group 2: Collaboration and Product Development - The Shandong Pharmaceutical Institute, a key player in Lushang Group's healthcare sector, recently won a provincial science and technology award for its innovative drug delivery technology, enhancing product efficacy and stability [4]. - Lushang Group's retail arm, Yinzou Group, is focused on deepening partnerships with manufacturers to streamline the supply chain and create a unique commercial ecosystem [4]. - The expo will feature products from various regions in Shandong, highlighting local specialties and Lushang's own brand offerings, thereby reconstructing an efficient demand-production-consumption chain [4]. Group 3: Strategic Initiatives - Yitong Jinfu Supply Chain is implementing the national "dual circulation" strategy by assisting companies like Weifang Sheng'an Food Co., Ltd. in transitioning from export to domestic sales [5]. - The Shandong Innovation Research Institute will showcase self-developed products under its brands, emphasizing high-quality offerings in the tea market [5]. - Lushang Group's wine division, Chateau de Cugat, ensures quality control from grape cultivation to consumer delivery, enhancing the supply chain's transparency and efficiency [6]. Group 4: Agricultural Practices - Lushang's agricultural operations focus on full-chain control from seed to shelf, utilizing standardized planting and traceable farming practices to ensure product quality [6]. - The company employs advanced techniques to maintain the nutritional integrity of its products, showcasing a commitment to sustainable agricultural practices [6]. Group 5: Overall Impact - The expo serves as a platform for Lushang Group to demonstrate its comprehensive supply chain innovations and achievements, with a focus on collaboration and sustainability [6].